In this issue:
Daratumumab regimens induce deep, durable remissions
MRD negativity is prognostic in myeloma
MRD conversion predicts clinical relapse
OCEAN trial of melflufen for RRMM on hold due to safety concerns
HORIZON: PROs in RRMM treated with melflufen/dexamethasone
Maintenance therapy after second transplant significantly improves outcomes
VRd and VCd induction regimens prior to ASCT confer comparable survival
Superior humoral immune response to infection versus vaccination in MM patients
Mass-Fix better predicts for PFS and OS than standard methods
TAK-580 plus selinexor demonstrates potent in vitro anti-myeloma activity
Please login below to download this issue (PDF)